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This came naturally with the implementation of tests out of the com-
petition period of the athletes. For an athlete, it has been observed 
that the homeostasis of biosynthesis and metabolism of endogenous 
hormones was not disturbed by sports activity but of course will be 
influenced by the intake of similar substances. Actually, the passport 
has been defined as an individual and longitudinal observation of 
biomarkers. These markers need to belong to the biological cascade 
influenced by the application of forbidden hormones or, more gen-
erally, affected by biological manipulations that can improve the 
performance of the athlete.
Nowadays, only the hematologic passport of an athlete has been 
officially set up. This is a statistical representation of the longitu-
dinal follow-up of some blood biomarkers. This individual and 
longitudinal follow-up of blood parameters is of interest because 
the intraindividual variability is lower than the corresponding inter-
individual variability. Among the key points for the implementa-
tion of the ABP is its possibility to resist to the legal and scientific 
challenges. The ABP should be implemented in the most possible 
transparent way in the process and with the necessary independ-
ence between planning, interpretation, and result management of 
the passport.
To reach this transparency and efficiency, a new major actor has 
been introduced in the system to create a framework of independ-
ence: The athlete Passport Management Unit (APMU). The World 
Antidoping Agency (WADA) did implement new dedicated technical 
documents associated with the passport (hematologic module). This 
was done to allow the correct implementation of a profile that can 
resist any scientific or legal critics in following strictly some steps in 
the chain of production of the results and in the management of the 
interpretation of the passport.
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Summary: Several million people are exposed to dioxin and dioxin-
like compounds, primarily through food consumption. Skin lesions 
historically called ‘‘chloracne’’ are the most specific sign of abnor-
mal dioxin exposure and classically used as a key marker in humans. 
We followed up for 5 years a man who had been exposed to the 
most toxic dioxin, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 
at a single oral dose of 5 million-fold more than the accepted 
daily exposure in the general population. We adopted a molecu-
lar medicine approach, aimed at identifying appropriate therapy. 
Skin lesions, which progressively covered up to 40% of the body 
surface, were found to be hamartomas, which developed parallel 
to a complete and sustained involution of sebaceous glands, with 
concurrent transcriptomic alterations pointing to the inhibition of 
lipid metabolism and the involvement of bone morphogenetic pro-
teins signaling. Hamartomas created a new compartment that con-
centrated TCDD up to 10-fold compared with serum and strongly 
expressed the TCDD-metabolizing enzyme cytochrome P-450 1A1, 
thus representing a potentially significant source of enzymatic activ-
ity, which may add to the xenobiotic metabolism potential of the 
classical organs such as the liver. This historical case provides a 
unique set of data on the human tissue response to dioxin for the 
identification of new markers of exposure in human populations. 
The herein discovered adaptive cutaneous response to TCDD also 
points to the potential role of the skin in the metabolism of food 
xenobiotics.
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Summary: In New Zealand, there has been discussion around the 
value of evidence-based medicine in primary care and the case for 
complementary practice-based evidence that could feed back into 
the evidence from clinical trials on the generality and applicability 
of the interventions in the “real-life” context.1 It is clear that data-
bases of adverse drug reaction (ADR) reports are, in fact, a source 
of practice-based evidence.
In 1965, New Zealand became 1 of the first countries to collect 
and assess reports submitted by health professionals of suspected 
ADRs in individual patients. This collection is the database of the 
Centre for Adverse Reactions Monitoring (CARM) based in the 
New Zealand Pharmacovigilance Centre. Distinctive features of the 
New Zealand database are the high proportion of well-documented 
reports, and, frequently, the highest reporting rate/population in 
international comparisons. New Zealand was also a founding mem-
ber of the WHO International Drug Monitoring Programme.
Databases of ADRs were established to generate hypotheses to be 
tested about previously unrecognized adverse reactions and interac-
tions. Occasionally, they contain sufficient evidence in themselves. 
They can also identify prescribing practices that might increase the 
potential for ADRs to occur. They can feed back into guidelines the 
consequences of their use or nonuse and identify unexpected prob-
lems that arise with issues such as pathways to accessing funded med-
icines. Well-documented ADR reports can also highlight risk factors, 
thus providing a valuable contribution to risk/benefit assessments in 
individual patients. Examples from the New Zealand database and 
from international collaboration will be discussed that support the 
use of ADR reports as practice-based evidence in a nonhierarchical 
system in which case reports and case series, observational studies, 
and randomized clinical trials contribute in a flexible relationship 
depending on the issue under investigation.
One of the major challenges in optimizing the contribution of 
ADR databases to clinical practice is the provision of feedback that 
aids prescribing and also stimulates the quality as well as quantity 
of reporting.
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Summary: Risk perception associated with medicines information 
affects drug therapy and drug adherence. One problem is inconsist-
encies between sources providing medicines information, which give 
